Drug Profile
Research programme: DNA topoisomerase inhibitors - Basilea Pharmaceutica
Alternative Names: BAL1; BAL2Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Basilea Pharmaceutica
- Class Antibacterials
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections